Operating Lease, Right-of-Use Asset of AGIOS PHARMACEUTICALS, INC. from 31 Mar 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
AGIOS PHARMACEUTICALS, INC. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Mar 2019 to 30 Sep 2025.
  • AGIOS PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $33,650,000, a 27% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

AGIOS PHARMACEUTICALS, INC. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $33,650,000 -$12,191,000 -27% 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $36,785,000 -$11,965,000 -25% 30 Jun 2025 10-Q 31 Jul 2025 2025 Q2
Q1 2025 $39,861,000 -$11,745,000 -23% 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $42,879,000 -$11,530,000 -21% 31 Dec 2024 10-Q 30 Oct 2025 2025 Q3
Q3 2024 $45,841,000 -$11,321,000 -20% 30 Sep 2024 10-Q 31 Oct 2024 2024 Q3
Q2 2024 $48,750,000 -$11,116,000 -19% 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 $51,606,000 -$10,915,000 -17% 31 Mar 2024 10-Q 02 May 2024 2024 Q1
Q4 2023 $54,409,000 -$10,720,000 -16% 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 $57,162,000 -$10,530,000 -16% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $59,866,000 -$10,348,000 -15% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $62,521,000 -$10,167,000 -14% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $65,129,000 -$9,995,000 -13% 31 Dec 2022 10-K 15 Feb 2024 2023 FY
Q3 2022 $67,692,000 -$9,840,000 -13% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 $70,214,000 -$9,687,000 -12% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $72,688,000 -$9,556,000 -12% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $75,124,000 -$9,537,000 -11% 31 Dec 2021 10-K 23 Feb 2023 2022 FY
Q3 2021 $77,532,000 -$9,420,000 -11% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $79,901,000 -$9,307,000 -10% 30 Jun 2021 10-Q 29 Jul 2021 2021 Q2
Q1 2021 $82,244,000 -$9,196,000 -10% 31 Mar 2021 10-Q 29 Apr 2021 2021 Q1
Q4 2020 $84,661,000 -$8,982,000 -9.6% 31 Dec 2020 10-K 24 Feb 2022 2021 FY
Q3 2020 $86,952,000 -$8,881,000 -9.3% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $89,208,000 -$9,292,000 -9.4% 30 Jun 2020 10-Q 30 Jul 2020 2020 Q2
Q1 2020 $91,440,000 +$33,672,000 +58% 31 Mar 2020 10-Q 30 Apr 2020 2020 Q1
Q4 2019 $93,643,000 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $95,833,000 30 Sep 2019 10-Q 31 Oct 2019 2019 Q3
Q2 2019 $98,500,000 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 $57,768,000 31 Mar 2019 10-Q 02 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.